Compare Stocks: MDXH, RLYB, GANX, and SERA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GANX Gain Therapeutics	$2.16 +1.9%	$1.80	$1.50 ▼ $4.34	$92.52M	0.19	503,297 shs	1.33 million shs
MDXH MDxHealth	$0.46 -1.6%	$0.47	$0.40 ▼ $5.33	$23.24M	1.42	238,036 shs	7.52 million shs
RLYB Rallybio	$16.96 +2.2%	$16.07	$3.67 ▼ $17.57	$88.10M	-0.9	28,121 shs	74,312 shs
SERA Sera Prognostics	$2.01 -0.5%	$1.99	$1.56 ▼ $3.95	$79.10M	0.96	38,638 shs	35,801 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GANX Gain Therapeutics	+1.89%	+21.35%	+28.57%	+23.43%	+39.35%
MDXH MDxHealth	-1.62%	+5.46%	+11.30%	-48.26%	-83.20%
RLYB Rallybio	+2.23%	+4.76%	+5.93%	+18.60%	+295.97%
SERA Sera Prognostics	-0.50%	+0.50%	+1.52%	+16.86%	-12.61%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GANX Gain Therapeutics	$2.16 +1.9%	$1.80	$1.50 ▼ $4.34	$92.52M	0.19	503,297 shs	1.33 million shs
MDXH MDxHealth	$0.46 -1.6%	$0.47	$0.40 ▼ $5.33	$23.24M	1.42	238,036 shs	7.52 million shs
RLYB Rallybio	$16.96 +2.2%	$16.07	$3.67 ▼ $17.57	$88.10M	-0.9	28,121 shs	74,312 shs
SERA Sera Prognostics	$2.01 -0.5%	$1.99	$1.56 ▼ $3.95	$79.10M	0.96	38,638 shs	35,801 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GANX Gain Therapeutics	+1.89%	+21.35%	+28.57%	+23.43%	+39.35%
MDXH MDxHealth	-1.62%	+5.46%	+11.30%	-48.26%	-83.20%
RLYB Rallybio	+2.23%	+4.76%	+5.93%	+18.60%	+295.97%
SERA Sera Prognostics	-0.50%	+0.50%	+1.52%	+16.86%	-12.61%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GANX Gain Therapeutics	2.67	Moderate Buy	$7.50	247.22% Upside
MDXH MDxHealth	2.40	Hold	$3.50	657.58% Upside
RLYB Rallybio	1.00	Sell	N/A	N/A
SERA Sera Prognostics	2.67	Moderate Buy	$5.50	173.63% Upside

Current Analyst Ratings Breakdown

Latest MDXH, RLYB, GANX, and SERA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2026	GANX Gain Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$5.00
8/5/2026	RLYB Rallybio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/31/2026	SERA Sera Prognostics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/16/2026	SERA Sera Prognostics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/1/2026	GANX Gain Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00
6/30/2026	GANX Gain Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$5.00
6/17/2026	SERA Sera Prognostics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/9/2026	GANX Gain Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/4/2026	SERA Sera Prognostics	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$6.00
5/27/2026	GANX Gain Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
5/14/2026	MDXH MDxHealth	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$7.00 ➝ $1.50

(Data available from 8/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GANX Gain Therapeutics	$50K	1,885.25	N/A	N/A	$0.48 per share	4.50
MDXH MDxHealth	$107.88M	0.21	N/A	N/A	($0.24) per share	-1.93
RLYB Rallybio	$860K	104.72	N/A	N/A	$17.79 per share	0.95
SERA Sera Prognostics	$80K	983.90	N/A	N/A	$1.94 per share	1.04

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GANX Gain Therapeutics	-$20.16M	-$0.58	N/A	N/A	N/A	N/A	-156.76%	-114.83%	N/A
MDXH MDxHealth	-$33.52M	-$0.65	N/A	N/A	N/A	-29.90%	N/A	-22.51%	N/A
RLYB Rallybio	-$8.98M	-$4.34	N/A	N/A	N/A	-911.07%	-40.53%	-38.13%	N/A
SERA Sera Prognostics	-$31.93M	-$0.65	N/A	N/A	N/A	-47,475.72%	-44.27%	-32.84%	N/A

Latest MDXH, RLYB, GANX, and SERA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	MDXH MDxHealth	-$0.1934	-$0.18	+$0.0134	-$0.22	$26.14 million	$27.21 million
8/12/2026	Q2 2026	SERA Sera Prognostics	-$0.1542	-$0.18	-$0.0258	-$0.18	$0.07 million	$0.03 million
8/11/2026	Q2 2026	GANX Gain Therapeutics	-$0.1380	-$0.11	+$0.0280	-$0.11	$0.03 million	N/A
8/6/2026	Q2 2026	RLYB Rallybio	-$1.28	-$1.09	+$0.19	$7.53	N/A	N/A
5/14/2026	Q1 2026	MDXH MDxHealth	-$0.1447	-$0.19	-$0.0454	-$0.17	$30.89 million	$23.90 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
GANX Gain Therapeutics	N/A	N/A	N/A	N/A	N/A
MDXH MDxHealth	N/A	N/A	N/A	N/A	N/A
RLYB Rallybio	N/A	N/A	N/A	N/A	N/A
SERA Sera Prognostics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GANX Gain Therapeutics	0.02	4.69	4.69
MDXH MDxHealth	N/A	1.63	1.46
RLYB Rallybio	N/A	27.26	27.26
SERA Sera Prognostics	N/A	2.12	2.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GANX Gain Therapeutics	11.97%
MDXH MDxHealth	N/A
RLYB Rallybio	90.34%
SERA Sera Prognostics	54.64%

Insider Ownership

Company	Insider Ownership
GANX Gain Therapeutics	4.15%
MDXH MDxHealth	1.70%
RLYB Rallybio	10.30%
SERA Sera Prognostics	11.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GANX Gain Therapeutics	20	43.64 million	40.88 million	Optionable
MDXH MDxHealth	300	49.50 million	48.66 million	Not Optionable
RLYB Rallybio	40	5.31 million	4.76 million	Not Optionable
SERA Sera Prognostics	120	39.16 million	34.73 million	Optionable

MDXH, RLYB, GANX, and SERA Headlines

Recent News About These Companies

Sera Prognostics, Inc.: Sera Prognostics Reports Second Quarter 2026 Financial Results

August 13 at 9:38 AM | finanznachrichten.de

Sera Prognostics Hits Key Milestones in Second Quarter 2026: Expanding Commercial Engagements and Unlocking Policy Momentum

August 12 at 11:42 PM | news.themarketisopen.comN

Sera Prognostics Q2 Earnings Call Highlights

August 12 at 10:03 PM | marketbeat.com

Sera Prognostics, Inc. (SERA) Q2 2026 Earnings Call Transcript

August 12 at 9:00 PM | seekingalpha.com

SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

August 12 at 6:39 PM | aol.comA

Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Misses Revenue Estimates

August 12 at 6:21 PM | zacks.com

Sera Prognostics (NASDAQ:SERA) Releases Quarterly Earnings Results, Misses Expectations By $0.03 EPS

August 12 at 5:40 PM | marketbeat.com

Sera Prognostics (SERA) Projected to Post Quarterly Earnings on Wednesday

August 11 at 1:10 AM | americanbankingnews.com

SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF SECOND QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON AUGUST 12, 2026

July 29, 2026 | prnewswire.com

Sera Prognostics (SERA) Expected to Announce Earnings on Wednesday

July 29, 2026 | marketbeat.com

PRIME SUBGROUP ANALYSIS DEMONSTRATES 22% REDUCTION IN NICU ADMISSIONS IN FIRST-TIME PREGNANCIES USING PreTRM® Test-GUIDED CARE

July 9, 2026 | prnewswire.com

SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF MARK CAPONE TO ITS BOARD OF DIRECTORS

June 30, 2026 | prnewswire.com

SERA PROGNOSTICS COLLABORATES ON ARPA-H AWARD TO ADVANCE POINT-OF-CARE DIAGNOSTIC FOR SAFER BIRTH

June 24, 2026 | prnewswire.com

SERA APPLAUDS ILLINOIS INITIATIVE TO EXPAND MEDICAID COVERAGE FOR PROTEOMIC BLOOD TESTING IN PREGNANCY

June 23, 2026 | prnewswire.com

All You Need to Know About Sera Prognostics (SERA) Rating Upgrade to Buy

June 19, 2026 | zacks.com

Sera Prognostics (NASDAQ:SERA) CFO Sells $11,315.20 in Stock

June 11, 2026 | insidertrades.com

Sera Prognostics Holds 2026 Annual Stockholders Meeting

June 4, 2026 | tipranks.com

SERA PROGNOSTICS ANNOUNCES BOARD TRANSITION

June 1, 2026 | prnewswire.com

Sera Prognostics (SERA) Loses 27% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

May 14, 2026 | zacks.com

Sera Prognostics, Inc.: Sera Prognostics Reports First Quarter 2026 Financial Results

May 9, 2026 | finanznachrichten.de

Will Sera Prognostics (NASDAQ:SERA) Spend Its Cash Wisely?

May 8, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDXH, RLYB, GANX, and SERA Company Descriptions

Gain Therapeutics NASDAQ:GANX

$2.16 +0.04 (+1.89%)

Closing price 08/13/2026 04:00 PM Eastern

Extended Trading

$2.17 +0.01 (+0.65%)

As of 04:00 AM Eastern

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

MDxHealth NASDAQ:MDXH

$0.46 -0.01 (-1.62%)

Closing price 08/13/2026 04:00 PM Eastern

Extended Trading

$0.51 +0.04 (+9.52%)

As of 04:18 AM Eastern

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

Rallybio NASDAQ:RLYB

$16.96 +0.37 (+2.23%)

Closing price 08/13/2026 04:00 PM Eastern

Extended Trading

$17.00 +0.04 (+0.25%)

As of 04:00 AM Eastern

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.

Sera Prognostics NASDAQ:SERA

$2.01 -0.01 (-0.50%)

Closing price 08/13/2026 04:00 PM Eastern

Extended Trading

$2.00 -0.01 (-0.75%)

As of 08/13/2026 04:10 PM Eastern

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MDXH, RLYB, GANX, and SERA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MDXH, RLYB, GANX, and SERA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MDXH, RLYB, GANX, and SERA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDXH, RLYB, GANX, and SERA Company Descriptions

Gain Therapeutics NASDAQ:GANX

MDxHealth NASDAQ:MDXH

Rallybio NASDAQ:RLYB

Sera Prognostics NASDAQ:SERA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MDXH, RLYB, GANX, and SERA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MDXH, RLYB, GANX, and SERA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MDXH, RLYB, GANX, and SERA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDXH, RLYB, GANX, and SERA Company Descriptions

Gain Therapeutics NASDAQ:GANX

MDxHealth NASDAQ:MDXH

Rallybio NASDAQ:RLYB

Sera Prognostics NASDAQ:SERA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools